Posted on

LOVE Pharma Inc. Announces Second Closing Of Financing

LOVE Pharma Inc. Announces Second Closing Of Financing

June 29, 2022

VANCOUVER, BC, CANADA (June 29, 2022) – LOVE Pharma Inc. (“LOVE” and or “the Company”) (CSE:LUV) (FSE: G1Q0), announces it has completed a second closing of its previously announced non-brokered private placement. The Company accepted subscriptions for 50,735,771 units at a price of $0.011 per unit, for gross proceeds of $558,093.50.  Each unit consists of one common share and one common share purchase warrant.  Each warrant entitles the holder to purchase one additional common share at $0.05 for a period of two years from the date of closing, subject to the option of the Company to accelerate the expiry date in the event that its shares trade at $0.15 or more for 10 consecutive days.

The Company paid $32,655.48  in cash and issued 2,968,680  broker warrants on the same terms as noted above, to qualified finders. Securities issued pursuant to this tranche are subject to trading restrictions until October 30, 2022.

Proceeds will be used for working capital and to review possible acquisitions.

About Love Pharma Inc.

With a focus on the global sexual Health and Wellness markets, Love Pharma Inc. (CSE: LUV) (FSE: G1Q0) was founded in 2020, with a mission to bring to market innovative products that enhance sexual health and wellness while providing an improved quality of life. Love Pharma holds exclusive licenses to produce market, package, sell, and distribute patent-protected therapeutic and pharmaceutical products throughout Europe, the United Kingdom, and North America.

For further information, please contact:

Investor Relations

Telephone: 1 (604) 343-2977

E-mail: investors@love-pharma.com

www.love-pharma.com

Neither the Canadian Securities Exchange nor its Regulation Services Provider (as that term is defined in the policies of the Canadian Securities Exchange) accepts responsibility for the adequacy or accuracy of this release.

Forward Looking Statements

Certain information set forth in this news release may contain forward-looking statements that involve substantial known and unknown risks and uncertainties. All statements other than statements of historical fact are forward-looking statements, including, without limitation, statements regarding future financial position, business strategy, use of proceeds, corporate vision, proposed acquisitions, partnerships, joint-ventures and strategic alliances and co-operations, budgets, cost and plans and objectives of or involving the Company. Such forward-looking information reflects management’s current beliefs and is based on information currently available to management. Often, but not always, forward-looking statements can be identified by the use of words such as “plans”, “expects”, “is expected”, “budget”, “scheduled”, “estimates”, “forecasts”, “predicts”, “intends”, “targets”, “aims”, “anticipates”, “may” or “believes” or variations (including negative variations) of such words and phrases or may be identified by statements to the effect that certain actions “may”, “could”, “should”, “would”, “might” or “will” be taken, occur or be achieved.  A number of known and unknown risks, uncertainties and other factors may cause the actual results or performance to materially differ from any future results or performance expressed or implied by the forward-looking information. These forward-looking statements are subject to numerous risks and uncertainties, certain of which are beyond the control of the Company including, but not limited to, the impact of general economic conditions, industry conditions, risks relating to epidemics or pandemics such as COVID–19, including the impact of COVID–19 on the Company’s business, financial condition and results of operations, lack of investor demand for Bitcoin and/or Bitcoin futures exchange traded funds, and dependence upon regulatory approvals. Readers are cautioned that the assumptions used in the preparation of such information, although considered reasonable at the time of preparation, may prove to be imprecise and, as such, undue reliance should not be placed on forward-looking statements. The Company does not assume any obligation to update or revise its forward-looking statements, whether as a result of new information, future events, or otherwise, except as required by securities laws.

Posted on

LOVE Pharma Inc. Announces First Closing of Financing

LOVE Pharma Inc. Announces First Closing of Financing

VANCOUVER, BC, CANADA (June 8, 2022) – LOVE Pharma Inc. (“LOVE” and or “the Company”) (CSE:LUV) (FSE: G1Q0), announces it has completed a first closing of a non-brokered private placement. The Company accepted subscriptions for 72,971,998 units at a price of $0.011 per unit, for gross proceeds of $802,691.99.  Each unit consists of one common share and one common share purchase warrant.  Each warrant entitles the holder to purchase one additional common share at $0.05 for a period of two years from the date of closing, subject to the option of the Company to accelerate the expiry date in the event that its shares trade at $0.15 or more for 10 consecutive days.

The Company paid $25,415.36  in cash and issued 2,310,487  broker warrants on the same terms as noted above, to qualified finders. Securities issued pursuant to this tranche are subject to trading restrictions until October 9, 2022.

Proceeds will be used for working capital and to review possible acquisitions.

About Love Pharma Inc.

With a focus on the global sexual Health and Wellness markets, Love Pharma Inc. (CSE: LUV) (FSE: G1Q0) was founded in 2020, with a mission to bring to market innovative products that enhance sexual health and wellness while providing an improved quality of life. Love Pharma holds exclusive licenses to produce market, package, sell, and distribute patent-protected therapeutic and pharmaceutical products throughout Europe, the United Kingdom, and North America.

For further information, please contact:

Investor Relations

Telephone: 1 (604) 343-2977

E-mail: investors@love-pharma.com

www.love-pharma.com

Neither the Canadian Securities Exchange nor its Regulation Services Provider (as that term is defined in the policies of the Canadian Securities Exchange) accepts responsibility for the adequacy or accuracy of this release.

Forward Looking Statements

Certain information set forth in this news release may contain forward-looking statements that involve substantial known and unknown risks and uncertainties. All statements other than statements of historical fact are forward-looking statements, including, without limitation, statements regarding future financial position, business strategy, use of proceeds, corporate vision, proposed acquisitions, partnerships, joint-ventures and strategic alliances and co-operations, budgets, cost and plans and objectives of or involving the Company. Such forward-looking information reflects management’s current beliefs and is based on information currently available to management. Often, but not always, forward-looking statements can be identified by the use of words such as “plans”, “expects”, “is expected”, “budget”, “scheduled”, “estimates”, “forecasts”, “predicts”, “intends”, “targets”, “aims”, “anticipates”, “may” or “believes” or variations (including negative variations) of such words and phrases or may be identified by statements to the effect that certain actions “may”, “could”, “should”, “would”, “might” or “will” be taken, occur or be achieved.  A number of known and unknown risks, uncertainties and other factors may cause the actual results or performance to materially differ from any future results or performance expressed or implied by the forward-looking information. These forward-looking statements are subject to numerous risks and uncertainties, certain of which are beyond the control of the Company including, but not limited to, the impact of general economic conditions, industry conditions, risks relating to epidemics or pandemics such as COVID–19, including the impact of COVID–19 on the Company’s business, financial condition and results of operations, lack of investor demand for Bitcoin and/or Bitcoin futures exchange traded funds, and dependence upon regulatory approvals. Readers are cautioned that the assumptions used in the preparation of such information, although considered reasonable at the time of preparation, may prove to be imprecise and, as such, undue reliance should not be placed on forward-looking statements. The Company does not assume any obligation to update or revise its forward-looking statements, whether as a result of new information, future events, or otherwise, except as required by securities laws.

Posted on

LOVE Pharma Announces Closing of Microdoz Therapy Acquisition

LOVE Pharma Announces Closing of Microdoz Therapy Acquisition

VANCOUVER, BC, CANADA (May 13, 2022) – LOVE Pharma Co. (“LOVE” and or “The Company”)(CSE: LUV) (FSE: G1Q0), is pleased to announce that it has completed its acquisition (the “Acquisition”) of MicroDoz Theraphy Inc. (“MicroDoz”) (as originally disclosed in a press release on November 23, 2021 and as updated on March 3, 2022).

Under the terms of the share exchange agreement (the “Share Exchange Agreement”) entered into among the Company, MicroDoz and the MicroDoz shareholders (the “MicroDoz Shareholders”), the Company will issue a total of 20,000,000 common shares of Love (the “Love Shares”) on a pro-rata basis at a deemed price of CAD $0.05 per Love Share for aggregate proceeds of CAD $1,000,000 and the current share price of the company as of todays date is $0.01 representing a discounted purchase price.

Upon closing of the Acquisition the Company issued to the MicroDoz Shareholders, on a pro-rata basis, 10,000,000 Love Shares in accordance with the Share Exchange Agreement. The remaining 10,000,000 Love Shares are subject to the fulfillment of certain milestones over a two (2) year period. In the event that the milestones are not met the Company will have no obligation to issue any further Love Shares and the total aggregate consideration for MicroDoz will be decreased accordingly. All Love Shares issued as part of the Acquisition will be subject to a resale restricted period of four months from the date of issuance and will bear a restrictive legend to this effect.

Lucas Corrubia, Co-founder of Microdoz and PhD Candidate, stated: “We are very pleased to finalize this transaction and join forces with Love Pharma.  We believe the combination of these two companies represents an exciting synergy in the promotion of mental wellness and development of novel therapies for mental health disorders”.

Zach Stadnyk, Love Pharma CEO, stated “This is a milestone achievement for the company to now be working on in partnership with researchers at Johns Hopkins, the worlds’ leading institution for psychedelic research, developing therapies for mental health disorders. We look forward to updating our shareholders and stakeholders as we achieve landmarks throughout this two-year partnership and ultimately commercialize the potential findings.”

About Love Pharma Inc.

With a focus on the global sexual Health and Wellness markets, Love Pharma Inc. (CSE: LUV) (FSE: G1Q0) was founded in 2020, with a mission to bring to market innovative products that enhance sexual health and wellness while providing an improved quality of life. Love Pharma holds exclusive licenses to produce market, package, sell, and distribute patent-protected therapeutic and pharmaceutical products throughout Europe, the United Kingdom, and North America.

The securities described herein to be issued in the Acquisition will be offered and sold in reliance upon available exemptions from the registration requirements under the U.S. Securities Act and have not been, and will not be, registered under the U.S. Securities Act, or any U.S. state securities laws, and may only be re-offered or re-sold in the United States pursuant to registration under the U.S. Securities Act and all applicable state securities laws or in compliance with the requirements of an applicable exemption therefrom.

This press release shall not constitute an offer to sell or the solicitation of an offer to buy securities in the United States, nor shall there be any sale of these securities in any jurisdiction in which such offer, solicitation or sale would be unlawful.

For further information, please contact:

 Investor Relations

Telephone: 1 (604) 343-2977

E-mail: investors@love-pharma.com

www.love-pharma.com

Cautionary Statement in Forward‐Looking Information

Neither the Canadian Securities Exchange nor its Regulation Services Provider (as that term is defined in the policies of the Canadian Securities Exchange) accepts responsibility for the adequacy or accuracy of this release. Certain statements contained in this release may constitute “forward–looking statements” or “forward-looking information” (collectively “forward-looking information”) as those terms are used in the Private Securities Litigation Reform Act of 1995 and similar Canadian laws. These statements relate to future events or future performance. The use of any of the words “could”, “intend”, “expect”, “believe”, “will”, “projected”, “estimated”, “anticipates” and similar expressions and statements relating to matters that are not historical facts are intended to identify forward-looking information and are based on the Company’s current belief or assumptions as to the outcome and timing of such future events. Actual future results may differ materially. In particular, this release contains forward-looking information relating to the business of the Company, financing and certain corporate changes. The forward-looking information contained in this release is made as of the date hereof and the Company is not obligated to update or revise any forward-looking information, whether as a result of new information, future events or otherwise, except as required by applicable securities laws. Because of the risks, uncertainties and assumptions contained herein, investors should not place undue reliance on forward-looking information. The foregoing statements expressly qualify any forward-looking information contained herein.

Posted on

Love Pharma Inc. Announces Closing of Financing

Love Pharma Inc. Announces Closing of Financing

VANCOUVER, BC, CANADA (May 6, 2022) – LOVE Pharma Inc. (“LOVE” and or “the Company”) (CSE:LUV) (FSE: G1Q0), announces it has completed the second tranche of a non-brokered private placement. The Company accepted subscriptions for 2,375,000 units at a price of $0.02 per unit, for gross proceeds of $47,500.  Each unit consists of one common share and one common share purchase warrant.  Each warrant entitles the holder to purchase one additional common share at $0.05 for a period of two years from the date of closing, subject to the option of the Company to accelerate the expiry date in the event that its shares trade at $0.15 or more for 10 consecutive days.

The Company paid $3,800  in cash and issued 190,000 broker warrants on the same terms as noted above, to qualified finders. Securities issued pursuant to this tranche are subject to trading restrictions until September 7, 2022.

Proceeds will be used for working capital and to review possible acquisitions.

About Love Pharma Inc.

 With a focus on the global sexual Health and Wellness markets, Love Pharma Inc. (CSE: LUV) (FSE: G1Q0) was founded in 2020, with a mission to bring to market innovative products that enhance sexual health and wellness while providing an improved quality of life. Love Pharma holds exclusive licenses to produce market, package, sell, and distribute patent-protected therapeutic and pharmaceutical products throughout Europe, the United Kingdom, and North America.

For further information, please contact:

Investor Relations

Telephone: 1 (604) 343-2977

E-mail: investors@love-pharma.com

www.love-pharma.com

Neither the Canadian Securities Exchange nor its Regulation Services Provider (as that term is defined in the policies of the Canadian Securities Exchange) accepts responsibility for the adequacy or accuracy of this release.

Forward Looking Statements

Certain information set forth in this news release may contain forward-looking statements that involve substantial known and unknown risks and uncertainties. All statements other than statements of historical fact are forward-looking statements, including, without limitation, statements regarding future financial position, business strategy, use of proceeds, corporate vision, proposed acquisitions, partnerships, joint-ventures and strategic alliances and co-operations, budgets, cost and plans and objectives of or involving the Company. Such forward-looking information reflects management’s current beliefs and is based on information currently available to management. Often, but not always, forward-looking statements can be identified by the use of words such as “plans”, “expects”, “is expected”, “budget”, “scheduled”, “estimates”, “forecasts”, “predicts”, “intends”, “targets”, “aims”, “anticipates”, “may” or “believes” or variations (including negative variations) of such words and phrases or may be identified by statements to the effect that certain actions “may”, “could”, “should”, “would”, “might” or “will” be taken, occur or be achieved.  A number of known and unknown risks, uncertainties and other factors may cause the actual results or performance to materially differ from any future results or performance expressed or implied by the forward-looking information. These forward-looking statements are subject to numerous risks and uncertainties, certain of which are beyond the control of the Company including, but not limited to, the impact of general economic conditions, industry conditions, risks relating to epidemics or pandemics such as COVID–19, including the impact of COVID–19 on the Company’s business, financial condition and results of operations, lack of investor demand for Bitcoin and/or Bitcoin futures exchange traded funds, and dependence upon regulatory approvals. Readers are cautioned that the assumptions used in the preparation of such information, although considered reasonable at the time of preparation, may prove to be imprecise and, as such, undue reliance should not be placed on forward-looking statements. The Company does not assume any obligation to update or revise its forward-looking statements, whether as a result of new information, future events, or otherwise, except as required by securities laws.

Posted on

Love Pharma Inc. Announces First Closing of Financing

Love Pharma Inc. Announces First Closing of Financing

VANCOUVER, BC, CANADA (April 5, 2022) – LOVE Pharma Inc. (“LOVE” and or “the Company”) (CSE:LUV) (FSE: G1Q0), announces it has completed a first closing of a non-brokered private placement. The Company accepted subscriptions for 16,550,000 units at a price of $0.02 per unit, for gross proceeds of $331,000.  Each unit consists of one common share and one common share purchase warrant.  Each warrant entitles the holder to purchase one additional common share at $0.05 for a period of two years from the date of closing, subject to the option of the Company to accelerate the expiry date in the event that its shares trade at $0.15 or more for 10 consecutive days.

The Company paid $9,050  in cash and issued 400,000 broker warrants on the same terms as noted above, to qualified finders. Securities issued pursuant to this tranche are subject to trading restrictions until August 6, 2022.

Proceeds will be used for working capital and to review possible acquisitions.

About Love Pharma Inc.

 With a focus on the global sexual Health and Wellness markets, Love Pharma Inc. (CSE: LUV) (FSE: G1Q0) was founded in 2020, with a mission to bring to market innovative products that enhance sexual health and wellness while providing an improved quality of life. Love Pharma holds exclusive licenses to produce market, package, sell, and distribute patent-protected therapeutic and pharmaceutical products throughout Europe, the United Kingdom, and North America.

For further information, please contact:

Investor Relations

Telephone: 1 (604) 343-2977

E-mail: investors@love-pharma.com

www.love-pharma.com

Neither the Canadian Securities Exchange nor its Regulation Services Provider (as that term is defined in the policies of the Canadian Securities Exchange) accepts responsibility for the adequacy or accuracy of this release.

Forward Looking Statements

Certain information set forth in this news release may contain forward-looking statements that involve substantial known and unknown risks and uncertainties. All statements other than statements of historical fact are forward-looking statements, including, without limitation, statements regarding future financial position, business strategy, use of proceeds, corporate vision, proposed acquisitions, partnerships, joint-ventures and strategic alliances and co-operations, budgets, cost and plans and objectives of or involving the Company. Such forward-looking information reflects management’s current beliefs and is based on information currently available to management. Often, but not always, forward-looking statements can be identified by the use of words such as “plans”, “expects”, “is expected”, “budget”, “scheduled”, “estimates”, “forecasts”, “predicts”, “intends”, “targets”, “aims”, “anticipates”, “may” or “believes” or variations (including negative variations) of such words and phrases or may be identified by statements to the effect that certain actions “may”, “could”, “should”, “would”, “might” or “will” be taken, occur or be achieved.  A number of known and unknown risks, uncertainties and other factors may cause the actual results or performance to materially differ from any future results or performance expressed or implied by the forward-looking information. These forward-looking statements are subject to numerous risks and uncertainties, certain of which are beyond the control of the Company including, but not limited to, the impact of general economic conditions, industry conditions, risks relating to epidemics or pandemics such as COVID–19, including the impact of COVID–19 on the Company’s business, financial condition and results of operations, lack of investor demand for Bitcoin and/or Bitcoin futures exchange traded funds, and dependence upon regulatory approvals. Readers are cautioned that the assumptions used in the preparation of such information, although considered reasonable at the time of preparation, may prove to be imprecise and, as such, undue reliance should not be placed on forward-looking statements. The Company does not assume any obligation to update or revise its forward-looking statements, whether as a result of new information, future events, or otherwise, except as required by securities laws.

Posted on

LOVE Pharma Updates Microdoz Proposed Acquisition With Global Leader in Psychedelic Research

LOVE Pharma Updates Microdoz Proposed Acquisition With Global Leader in Psychedelic Research

  • This comprehensive study relating to the potential of psilocybin assisted treatment for cannabis use disorder will help to establish consumer confidence and differentiate LOVE Pharma treatments in the marketplace
  • The World Health Organization notes that Cannabis is the “most commonly used psychoactive substance under international control, and that there is increasing demand of treatment for cannabis use disorders”1

VANCOUVER, BC, CANADA (March 3, 2022) – LOVE Pharma Co. (“LOVE” and or “The Company”)(CSE: LUV) (FSE: G1Q0), the Company is pleased to announce updated details on the proposed Microdoz Therapy acquisition (originally announced in a press release on November 23, 2021), whereby Microdoz has engaged exclusively with researchers at Johns Hopkins University, the top psychedelic center in the World, located in the eastern United States, to conduct a landmark study into the potential of psilocybin assisted treatment of cannabis use disorder. The company looks forward to working with the university and research experts on the study and, ultimately, licensing and commercializing the intellectual property developed by the landmark study.

“This is a significant opportunity to develop treatments with efficacy for people who are today subject to Cannabis Use Disorder and those who will become subject to it in the future,” said Mr. Zach Stadnyk, Love Pharma CEO. “The U.S. cannabis industry is forecast to surpass $41 billion by 20252, and the National Institute on Drug Abuse has released research suggesting 9% – 30% of people using cannabis may develop cannabis use disorder3, so we see an opportunity where Love can help people facing this disorder along with our research partners, while at the same time developing a lucrative market for treatment that will benefit our shareholders.”

Lucas Corrubia, Co-founder of Microdoz and PhD Candidate, stated: “the Hopkins team has paved the way for clinical psychedelic therapy research, and we are optimistic in working with their successful research team to develop a new therapy for cannabis abuse, and develop a long-lasting relationship with the global leader in medical research sciences”.

Through the planned acquisition of Microdoz, partnering with the university to conduct this comprehensive study relating to the potential of psilocybin assisted treatment for cannabis use disorder will help to establish consumer confidence and guide the development and use of psilocybin product development and application.  As a result, LOVE will continue to develop innovative products that establish new consumer applications. Science and efficacy are paramount to the LOVE Pharma strategy, as indicated by the Company’s research initiative to take place at Johns Hopkins. We look forward to completing this clinical study and licensing the intellectual property produced from it and, eventually, commercializing the prospective findings furthering our footprint in the bourgeoning psychedelics for therapeutic use space going forward and delivering value for our shareholders.

Terms of the Deal:

  • $1,000,000 CAD payable in common shares of the company subject to certain escrow provisions pegged to milestone achievements at a deemed price of $0.05 per share
  • 50% payable at closing of the definitive agreement which is anticipated to close in 14 days, subject to final due diligence
  • Remaining 50% will be paid in four equal tranches over a 2-year period subject to the successful completion of certain millstones
  1. https://www.who.int/teams/mental-health-and-substance-use/alcohol-drugs-and-addictive-behaviours/drugs-psychoactive/cannabis
  2. https://www.bloomberg.com/news/articles/2021-06-08/cannabis-addiction-draws-drugmakers-in-search-for-a-treatment
  3. https://nida.nih.gov/publications/drugfacts/marijuana
  4. https://nida.nih.gov/publications/research-reports/marijuana/available-treatments-marijuana-use-disorders

This acquisition is subject to final due diligence, and it is anticipated to close in the coming weeks, for which, there is no guarantee.

In addition, pursuant to the company’s stock option plan, the company has issued 3,000,000 inventive stock options to consultants of the issuer exercisable at a price of $0.05 per share for a period of five (5) years, vesting immediately.

Zachary Stadnyk, CEO and Director

About Love Pharma Inc.

With a focus on the global sexual Health and Wellness markets, Love Pharma Inc. (CSE: LUV) (FSE: G1Q0) was founded in 2020, with a mission to bring to market innovative products that enhance sexual health and wellness while providing an improved quality of life.  Love Pharma holds exclusive licenses to produce market, package, sell, and distribute patent-protected therapeutic and pharmaceutical products throughout Europe, the United Kingdom, and North America.

For further information, please contact:

Investor Relations

Telephone: 1 (604) 343-2977

E-mail: investors@love-pharma.com

www.love-pharma.com

Neither the Canadian Securities Exchange nor its Regulation Services Provider (as that term is defined in the policies of the Canadian Securities Exchange) accepts responsibility for the adequacy or accuracy of this release.

Certain statements contained in this release may constitute “forward–looking statements” or “forward-looking information” (collectively “forward-looking information”) as those terms are used in the Private Securities Litigation Reform Act of 1995 and similar Canadian laws. These statements relate to future events or future performance. The use of any of the words “could”, “intend”, “expect”, “believe”, “will”, “projected”, “estimated”, “anticipates” and similar expressions and statements relating to matters that are not historical facts are intended to identify forward-looking information and are based on the Company’s current belief or assumptions as to the outcome and timing of such future events. Actual future results may differ materially. In particular, this release contains forward-looking information relating to the business of the Company, financing and certain corporate changes. The forward-looking information contained in this release is made as of the date hereof and the Company is not obligated to update or revise any forward-looking information, whether as a result of new information, future events or otherwise, except as required by applicable securities laws. Because of the risks, uncertainties and assumptions contained herein, investors should not place undue reliance on forward-looking information. The foregoing statements expressly qualify any forward-looking information contained herein.

Posted on

LOVE Pharma (LUV) To Acquire Microdoz Therapy Inc. To Expedite Study Of Psilocybin Assisted Treatment Of Cannabis Use Disorder

LOVE Pharma (LUV) To Acquire Microdoz Therapy Inc. To Expedite Study Of Psilocybin Assisted Treatment Of Cannabis Use Disorder

LOVE Pharma (LUV) signed a letter of intent to acquire Microdoz Therapy Inc. to accelerate a psilocybin trial for cannabis use disorder. Seems ironic considering that the company also sells THC and CBD oral strips!

 

Posted on

LOVE Pharma Signs Letter Of Intent To Acquire 100% Interest In Microdoz Therapy Inc. To Expedite Pilot Study Of Psilocybin Assisted Treatment Of Cannabis Use Disorder With World Leading University

LOVE Pharma Signs Letter Of Intent To Acquire 100% Interest In Microdoz Therapy Inc. To Expedite Pilot Study Of Psilocybin Assisted Treatment Of Cannabis Use Disorder With World Leading University

VANCOUVER, BC, CANADA (November 23, 2021) – LOVE Pharma Inc. (“LOVE” and or the “Company”)(CSE: LUV) (FSE: G1Q0), is pleased to announce that it has executed a Letter of Intent (”LOI”) to acquire 100% of MicroDoz Therapy Inc. (“MicroDoz”), which has an exclusive partnership and license with a world leading university to conduct a landmark study into the efficacy of psilocybin assisted treatment of cannabis use disorder. Upon the closing of the definitive agreement, the Company expects to release the details of the program and university partner.

This new partnership and development program will add to the Company’s comprehensive portfolio of intellectual property and further validate the Company’s effort to be a frontrunner in the psychedelics and therapeutics space.

Terms of the Deal:

  • $1,000,000 CAD payable in common shares of the Company subject to certain escrow provisions at a deemed price of $0.05 per share
  • 50% payable at closing of the proposed transaction which is anticipated to close in 30 days
  • Remaining 50% will be paid in four equal tranches over a 2-year period subject to the successful completion of certain milestones to be established in the definitive agreement

“LOVE’s existing portfolio is at the leading edge of innovation and our new product development will continue to build upon that foundation, aiming to establish new customer applications as we seek to define the psychedelics and therapeutics space,”  said Mr. Zach Stadnyk, LOVE President and CEO. “Science and efficacy are paramount to our strategy, as a result we seized the opportunity to acquire MicroDoz to expedite what will be a landmark study with a world leading university to establish our Biosynthetic Psilocybin Infused Oral Strip as a product with the highest standard of efficacy, establishing the highest level of consumer confidence.“

In addition, pursuant to the company’s stock option plan, the Company has issued 19,250,000 incentive stock options to certain officers, directors, employees, and consultants of the issuer exercisable at a price of $0.05 per share for a period of five (5) years, vesting immediately.


About Love Pharma Inc.

With a focus on the global sexual Health and Wellness markets, LOVE Pharma Inc. (CSE: LUV) (FSE: G1Q0) was founded in 2020, with a mission to bring to market innovative products that enhance sexual health and wellness while providing an improved quality of life.  LOVE Pharma Inc. holds exclusive licenses to produce market, package, sell, and distribute patent-protected therapeutic and pharmaceutical products throughout Europe, the United Kingdom, and North America.

For further information, please contact:

Investor Relations

Telephone: 1 (604) 343-2977

E-mail: investors@love-pharma.com

www.love-pharma.com

Neither the Canadian Securities Exchange nor its Regulation Services Provider (as that term is defined in the policies of the Canadian Securities Exchange) accepts responsibility for the adequacy or accuracy of this release.

Forward Looking Statement Disclaimer

This press release contains forward-looking statements and forward-looking information within the meaning of applicable securities legislation (together, “forward-looking statements”. Forward-looking statements can be identified by the expressions “seeks”, “expects”, “believes”, “estimates”, “will”, “target” and similar expressions. The forward-looking statements are not historical facts, but reflect the current expectations of the Company regarding future results or events and are based on information currently available to them. Certain material factors and assumptions were applied in providing these forward-looking statements. The forward-looking events and circumstances discussed in this release include, but are not limited to, the acquisition of MicroDoz and the timing of the acquisition, the possibility of success associated with the study, the ability of the Company to fulfill all conditions to closing, and the outcome and anticipated benefits of the acquisition. All forward-looking statements in this press release are qualified by these cautionary statements. The Company believes that the expectations reflected in forward-looking statements are based upon reasonable assumptions; however, the Company can give no assurance that the actual results or developments will be realized by certain specified dates or at all. These forward-looking statements are subject to a number of risks and uncertainties that could cause actual results or events to differ materially from current expectations. Readers, therefore, should not place undue reliance on any such forward-looking statements. Further, a forward-looking statement speaks only as of the date on which such statement is made. The Company undertakes no obligation to publicly update any such statement or to reflect new information or the occurrence of future events or circumstances except as required by securities laws. These forward-looking statements are made as of the date of this press release. These forward-looking statements may be affected by risks and uncertainties in the business of Appreciated and Trinity and general market conditions, including COVID-19.

Posted on

Is MDMA the Viagra for women?

LOVE PHARMA INC., ANNOUNCES LISTING ON FRANKFURT STOCK EXCHANGE

A Vancouver company called LOVE Pharma (LUV) wants to promote mental and sexual wellness with its growing product line.

The company recently launched two products (a CBD oral strip and a clitoral stimulation gel) and has exclusive rights to a total of seven novel therapeutic products. It’s currently developing a biosynthetic psilocybin strip using the IP from the CBD strip.

On Tuesday, the company was listed on  the Frankfurt Stock Exchange under the symbol “G1Q0”.

In other sexual wellness news, Mindcure (MCUR) recently launched a research program to treat female hypoactive sexual desire disorder (HSDD), a disorder involving low sex drive and emotional distress, with MDMA-assisted therapy.

PDF of article 1

PDF of article 2